Skip to main content

01.03.2013 | Original Paper | Ausgabe 1/2013

Medical Oncology 1/2013

Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma

Medical Oncology > Ausgabe 1/2013
Bing Bai, Hui-Qiang Huang, Qi-Chun Cai, Wei Fan, Xiao-Xiao Wang, Xu Zhang, Ze-Xiao Lin, Yan Gao, Yun-Fei Xia, Ying Guo, Qing-Qing Cai, Wen-Qi Jiang, Tong-Yu Lin
Wichtige Hinweise
Bing Bai, Hui-Qiang Huang and Qi-Chun Cai contributed equally to this work.


The role of 18Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in extranodal natural killer/T-cell lymphoma (ENKL) is not well established. This study aimed to investigate the prognostic role of the pretreatment maximum standardized uptake value (SUVmax) on PET/CT in patients with newly diagnosed ENKL. Among 364 consecutive patients with newly diagnosed ENKL, 81 patients were included and reviewed. The impact of SUVmax on survival and the relationship between SUVmax and other clinicopathological parameters were analyzed. The median SUVmax was 14.6 (range 2.0–45.4). The optimal cutoff value of SUVmax to predict overall survival (OS) was 15. Patients with high SUVmax (SUVmax >15) were associated with bulky disease (P < 0.001), local invasion (P = 0.030), high score of Korean Prognostic Index (KPI, P = 0.046), resistance to primary treatment (P = 0.014), poor OS (P < 0.001), and unfavorable progression-free survival (P < 0.001). With a median follow-up of 25.0 months, the median OS was 63.0 months (range 2.0–99.0 months). Multivariate analyses revealed the following independent prognostic factors for OS: age >60 years (P = 0.001), stage III–IV (P = 0.023), SUVmax >15 (P = 0.020), and bulky disease (>5 cm) (P = 0.002). By using the SUVmax, patients in most subgroups stratified by the KPI or the International Prognostic Index (IPI) were further discriminated in OS with significant statistical difference. Our results suggest the pretreatment SUVmax is predictive of prognosis in patients with newly diagnosed ENKL. The SUVmax may provide additional prognostic information for IPI and KPI.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.